Skip to content

Esophageal Cancer Multimodal Prehabilitation Study

A Multimodal Prehabilitation Feasibility Study for Older Adult Patients at High Risk for Poor Postoperative Outcomes Prior to Esophageal Cancer Surgery

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06027515
Enrollment
15
Registered
2023-09-07
Start date
2023-12-01
Completion date
2026-01-31
Last updated
2026-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Esophageal Neoplasms

Keywords

Esophageal Cancer, Esophageal Neoplasms

Brief summary

The goal of this research study is to investigate the feasibility of implementing a prehabilitation program that aims to improve a patient's physical, nutritional, and sleep health before surgery in an older, at-risk group with esophageal cancer.

Detailed description

This research study is to test whether a novel, 4-week surgical multimodal prehabilitation protocol is feasible in at-risk older adult patients who have previously undergone neoadjuvant chemotherapy or radiotherapy and are scheduled for surgical removal of esophageal cancer. Research study procedures include screening for eligibility, clinic visits, questionnaires, blood tests, and Computed Tomography (CT) scans. Participation in this research study is expected to last 7 months. It is expected about 30 patients will participate in this study.

Interventions

Multimodal prehabilitation program consisting of pre-surgical optimization of nutrition, physical function, and sleep health via individualized plans. Participants will also be supplied with Nestle Impact Advances Recovery Immunonutrition Drink.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 65 years of age and over * Adult male or non-pregnant female volunteers * Completed neoadjuvant chemotherapy or radiotherapy for esophageal cancer * At least four weeks to esophageal cancer surgery * Without skin conditions that preclude wearing sensors * Able to speak English and consent

Exclusion criteria

* Participants in any other interventional study that may bias results or limit study adherence during our study * Dietary restrictions that prevent consumption of nutritional supplements * Women who are pregnant, nursing, or at risk of becoming pregnant * Profound physical disability (for example, quadriplegia) that precludes participation in any aerobic or strength training.

Design outcomes

Primary

MeasureTime frameDescription
Enrollment Rate (Feasibility)At screeningNumber of eligible patients who enroll in study
Completion Rate (Feasibility)30 daysDefined as the number of patients who complete study procedures.

Secondary

MeasureTime frameDescription
Nutrition Compliance Rate (Feasibility)5 daysComparison of number of nutritional supplements consumed compared to number of nutritional supplements prescribed as determined from daily check-ins. A cut-off value of 80% will be used to indicate compliance.
Physical Function Compliance Rate (Feasibility)30 daysComparison of the total minutes of physical function completed compared to the total minutes of physical function prescribed as determined from daily check-ins and wearable device. A cut-off value of 80% will be used to indicate compliance.
Sleep Health Compliance Rate (Feasibility)30 daysComparison of the average daily hours of sleep duration, minutes of wake after sleep onset, and variability in sleep timing, achieved compared to prescribed as determined from actigraphy. A cut-off value of 80% will be used to indicate compliance.
Actigraphy Compliance Rate (Feasibility)30 daysTotal daily hours of actiwatch/wearable device wear-time. A cut-off value of 80% will be used to indicate compliance.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORHassan Dashti, PhD

Massachusetts General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026